• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Celladon

edit

Celladon Corporation, a biotechnology company, develops and manufactures molecular therapies for the treatment of heart failure. Its products include SERCA2a, an enzyme that regulates calcium cycling and contractility in heart muscle cells; and MYDICAR, an enzyme replacement therapy for heart failure. The company was founded in 2000 and is based in La Jolla, California.

Recent Milestones

edit

• 
  Celladon received $10M in Venture Round funding. (5/8/12)
  Posted 5/8/12 at 6:55pm via finsmes.com
• 
  Celladon received $43M in Venture Round funding. (2/15/12)
  Posted 2/15/12 at 6:31pm via finsmes.com
• 
  Celladon received $21.8M in Series C funding. (11/1/09)
  Posted 11/2/09 at 6:45pm via onbiovc.com
• 
  Celladon received $30M in Series B funding. (12/7/05)
  Posted 7/1/10 at 11:48pm via thefreelibrary.com
• 
  Celladon added Krisztina M. Zsebo as CEO.
  Posted 11/2/09 at 6:45pm
• 
  Celladon added Roger Hajjar as Co-Founder and Scientific Advisor.
  Posted 11/2/09 at 6:45pm

Videos

Screenshots

edit

Above: Home Page
Uploaded: 2/16/12

Sources

1. Celladon Secures $30 Million in Series B Financing. (thefreelibrary.com) [edit]
2. Celladon, Inc.: Series C $21.8M (onbiovc.com) [edit]
3. Celladon Closes $43M in Funding (finsmes.com) [edit]
4. Celladon Raises Additional $10M (finsmes.com) [edit]